Platelets and heart failure.
Heart failure is associated with increased risk of venous thromboembolism, stroke, and sudden death. Platelet abnormalities have been well described in heart failure but the significance of platelets in contributing to the thromboembolic complications of heart failure remains uncertain. Furthermore, the role of antiplatelet agents in heart failure remains unclear. This review will focus on platelet activation and the role of platelet dysfunction in heart failure, with particular regard to pathophysiology and outcome. The effects of heart failure therapeutics on platelet function and antiplatelet therapy in heart failure will also be discussed.
Chung
Irene
I
Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Lip
Gregory Y H
GY
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001791:Blood Platelet Disorders / Q000150:complications* / Q000503:physiopathology; D016207:Cytokines / Q000502:physiology; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000209:etiology* / Q000503:physiopathology; D006801:Humans; D009569:Nitric Oxide / Q000502:physiology; D015539:Platelet Activation / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D016207:Cytokines; D004232:Diuretics; D010975:Platelet Aggregation Inhibitors; D009569:Nitric Oxide